Search

Corvus Pharmaceuticals Inc

Gesloten

15.19 2.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.62

Max

14.96

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+98.12% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

32M

1.2B

Vorige openingsprijs

13.11

Vorige sluitingsprijs

15.19

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 aug 2026, 23:51 UTC

Cryptocurrency Declines Reflect Broader Investor Caution Amid Economic Uncertainties and Geopolitical Tensions.

16 aug 2026, 23:51 UTC

Japan's GDP growth data highlights economic recovery amid global caution, while U.S. retail sales drop raises concerns over interest rate hikes and geopolitical tensions impact financial stability.

16 aug 2026, 23:51 UTC

Cryptocurrency and major indices decline amid economic uncertainties, with Bridgewater warning of "crunch time" for capital expenditures and consumer sentiment dropping sharply.

16 aug 2026, 23:51 UTC

Bitcoin and Ethereum decline as major indices show mixed performance amid cautious market sentiment and concerns over capital expenditures.

16 aug 2026, 23:51 UTC

NAHB Housing Market Index for August 2026 set to release with forecast of 33.0 amid cautious sentiment and declining builder confidence.

16 aug 2026, 23:51 UTC

Correlated Moves
Macro News

Bitcoin is lower at $63,022 amid broader market pressures from mixed cryptocurrency movements and recent economic data showing declining U.S. retail sales.

16 aug 2026, 23:41 UTC

Japan's GDP Growth Preliminary Release Expected to Show Modest +0.02% Year-over-Year Increase Amid Mixed Regional Economic Sentiment

16 aug 2026, 23:41 UTC

Japan's Q2 GDP Growth Rate Expected at 0.5% Amid Cautious Market Sentiment and Rising Oil Prices

16 aug 2026, 23:41 UTC

China's July Retail Sales YoY data set for August 17, 2026, forecasts a rise to 1.5%, signaling cautious optimism amid mixed economic indicators.

16 aug 2026, 23:41 UTC

China's Industrial Production YoY data for July 2026 set to release with a forecasted growth rate of 5.0%, amid cautious market sentiment and concerns over declining fixed asset investment.

16 aug 2026, 23:41 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.5% in June Amid Mixed Economic Sentiment

16 aug 2026, 23:41 UTC

China's Fixed Asset Investment Expected to Decline by 6.2% YoY, Raising Concerns Over Economic Growth

16 aug 2026, 23:31 UTC

U.S. Industrial Production MoM data for July 2026 set to release on August 18, with cautious optimism amid mixed signals and a forecasted increase of 0.3%.

16 aug 2026, 23:21 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Cautious Optimism and Mixed Economic Signals on August 20, 2026.

16 aug 2026, 23:21 UTC

Canada's New Housing Price Index set for release amid cautious optimism and government infrastructure investments aimed at stabilizing home prices.

16 aug 2026, 23:11 UTC

China's House Price Index YoY release on August 17, 2026, may reveal ongoing pressures in the housing market amid cautious economic indicators and mixed global market performance.

16 aug 2026, 23:02 UTC

Correlated Moves

USD/SEK is lower during after-market hours, continuing a downward trend since Friday. Broader market dynamics are influencing the currency pair's movement.

16 aug 2026, 23:01 UTC

CAD/JPY shows a modest increase in after-hours trading, maintaining an upward trajectory since Friday's close amid a generally positive trading context.

16 aug 2026, 23:01 UTC

Macro News

The US 30Y Treasury Bond Index is trading lower as mixed China economic data raises concerns about global growth prospects. It pulled back from earlier session highs.

16 aug 2026, 23:01 UTC

The US 10Y Treasury Bond Index is lower today, trading down from Friday's close. The index remains in the middle of its one-month range.

16 aug 2026, 23:01 UTC

The CAD/CHF currency pair is higher in after-market hours, reflecting notable strength and unusual activity. It is positioned above its 20-day moving average.

16 aug 2026, 23:01 UTC

GBP/CHF is trading higher during after-market hours, maintaining a steady upward movement since Friday's close. The asset remains near the upper end of its one-month range.

16 aug 2026, 23:01 UTC

Gold and silver are trading higher during Sunday’s session, gaining ground since Friday's close. Key economic data from China is expected tomorrow.

16 aug 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and maintaining a position above its 20-day moving average.

16 aug 2026, 23:01 UTC

Correlated Moves

Gold/SGD is higher today, reflecting a modest increase since Friday's close. The asset remains above its 20-day moving average amid rising silver prices.

16 aug 2026, 23:01 UTC

Correlated Moves

Gold/JPY is trading higher, reflecting a slight increase since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

16 aug 2026, 23:01 UTC

Correlated Moves

Gold/HKD is advancing during the session, reflecting a broader trend as silver also gains. The asset remains above its 20-day moving average.

16 aug 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading higher, reflecting a modest advance since Friday's close. The asset remains above its 20-day moving average and near recent highs.

16 aug 2026, 23:01 UTC

Correlated Moves

Silver/JPY is higher today, supported by a rise in gold and anticipation of key economic data from China.

16 aug 2026, 23:01 UTC

Correlated Moves

Silver/SGD is rising in the current session, supported by a broader trend in precious metals, with gold also gaining.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

98.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  98.12%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat